EZH2 expression in invasive lobular carcinoma of the breast

World Journal of Surgical Oncology

Volumn 11, Issue , 2013, Pages

  Roh, SiGyun ^b   Park, Shin Y ^a   Ko, Hyoung S ^a   Sohn, Jang S ^a   Cha, Eun J ^a  

^a Konyang University College of Medicine   (South Korea)

^b Chonbuk National University Medical School   (South Korea)

Author keywords

Breast; Enhancer of Zeste 2; EZH2; Lobular carcinoma

Indexed keywords

ESTROGEN RECEPTOR; PROGESTERONE RECEPTOR; TRANSCRIPTION FACTOR EZH2;

ADULT; ARTICLE; BODY MASS; BREAST CARCINOMA; CANCER PROGNOSIS; CANCER SURVIVAL; DISEASE SEVERITY; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MEDICAL RECORD REVIEW; MENSTRUATION; MITOSIS; PREDICTION; PRIMARY TUMOR; PROTEIN EXPRESSION; RETROSPECTIVE STUDY;

BREAST NEOPLASMS; CARCINOMA, LOBULAR; CELL NUCLEUS; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOENZYME TECHNIQUES; LYMPHATIC METASTASIS; MIDDLE AGED; NEOPLASM INVASIVENESS; NEOPLASM STAGING; POLYCOMB REPRESSIVE COMPLEX 2; PROGNOSIS; RETROSPECTIVE STUDIES; TUMOR MARKERS, BIOLOGICAL;

EID: 84887897534     PISSN: None     EISSN: 14777819     Source Type: Journal    
DOI: 10.1186/1477-7819-11-299     Document Type: Article

References (21)

1. Banaszak AT, LaJeunesse TC, Trench RK. The synthesis of mycosporine-like amino acids (MAAs) by cultured, symbiotic dinoflagellates. J Exp Mar Bio Ecol 2000, 249:219-233. 10.1016/S0022-0981(00)00192-1, 10841936.
2. Kerlikowske K, Molinaro A, Cha I, Ljung BM, Ernster VL, Stewart K, Chew K, Moore DH, Waldman F. Characteristics associated with recurrence among women with ductal carcinoma in situ treated by lumpectomy. J Natl Cancer Inst 2003, 95:1692-1702. 10.1093/jnci/djg097, 14625260.
3. Lancet T. International classification of breast tumours. Lancet 1968, 292:719-720.
4. Viré E, Brenner C, Deplus R, Blanchon L, Fraga M, Didelot C, Morey L, Van Eynde A, Bernard D, Vanderwinden JM, Bollen M, Esteller M, Di Croce L, de Launoit Y, Fuks F. The polycomb group protein EZH2 directly controls DNA methylation. Nature 2006, 439:871-874.
5. Varambally S, Dhanasekaran SM, Zhou M, Barrette TR, Kumar-Sinha C, Sanda MG, Ghosh D, Pienta KJ, Sewalt RG, Otte AP, Rubin MA, Chinnaiyan AM. The polycomb group protein EZH2 is involved in progression of prostate cancer. Nature 2002, 419:624-629. 10.1038/nature01075, 12374981.
6. Liu DC, Yang ZL. Overexpression of EZH2 and loss of expression of PTEN is associated with invasion, metastasis, and poor progression of gallbladder adenocarcinoma. Pathol Res Pract 2011, 207:472-478. 10.1016/j.prp.2011.05.010, 21719208.
7. Wagener N, Macher-Goeppinger S, Pritsch M, Husing J, Hoppe-Seyler K, Schirmacher P, Pfitzenmaier J, Haferkamp A, Hoppe-Seyler F, Hohenfellner M. Enhancer of Zeste homolog 2 (EZH2) expression is an independent prognostic factor in renal cell carcinoma. BMC Cancer 2010, 10:524. 10.1186/1471-2407-10-524, 2958940, 20920340.
8. Arpino G, Bardou VJ, Clark GM, Elledge RM. Infiltrating lobular carcinoma of the breast: tumor characteristics and clinical outcome. Breast Cancer Res 2004, 6:R149-R156. 10.1186/bcr767, 400666, 15084238.
9. Cao Q, Yu J, Dhanasekaran SM, Kim JH, Mani RS, Tomlins SA, Mehra R, Laxman B, Cao X, Yu J, Kleer CG, Varambally S, Chinnaiyan AM. Repression of E-cadherin by the polycomb group protein EZH2 in cancer. Oncogene 2008, 27:7274-7284. 10.1038/onc.2008.333, 2690514, 18806826.
10. Kleer CG, Cao Q, Varambally S, Shen R, Ota I, Tomlins SA, Ghosh D, Sewalt RG, Otte AP, Hayes DF, Sabel MS, Livant D, Weiss SJ, Rubin MA, Chinnaiyan AM. EZH2 is a marker of aggressive breast cancer and promotes neoplastic transformation of breast epithelial cells. Proc Natl Acad Sci USA 2003, 100:11606-11611. 10.1073/pnas.1933744100, 208805, 14500907.
11. Ding L, Erdmann C, Chinnaiyan AM, Merajver SD, Kleer CG. Identification of EZH2 as a molecular marker for a precancerous state in morphologically normal breast tissues. Cancer Res 2006, 66:4095-4099. 10.1158/0008-5472.CAN-05-4300, 16618729.
12. Orvieto E, Maiorano E, Bottiglieri L, Maisonneuve P, Rotmensz N, Galimberti V, Luini A, Brenelli F, Gatti G, Viale G. Clinicopathologic characteristics of invasive lobular carcinoma of the breast: results of an analysis of 530 cases from a single institution. Cancer 2008, 113:1511-1520. 10.1002/cncr.23811, 18704988.
13. Droufakou S, Deshmane V, Roylance R, Hanby A, Tomlinson I, Hart IR. Multiple ways of silencing E-cadherin gene expression in lobular carcinoma of the breast. Int J Cancer 2001, 92:404-408. 10.1002/ijc.1208, 11291078.
14. Gonzalez ME, Li X, Toy K, DuPrie M, Ventura AC, Banerjee M, Ljungman M, Merajver SD, Kleer CG. Downregulation of EZH2 decreases growth of estrogen receptor-negative invasive breast carcinoma and requires BRCA1. Oncogene 2009, 28:843-853. 10.1038/onc.2008.433, 2643353, 19079346.
15. Alford SH, Toy K, Merajver SD, Kleer CG. Increased risk for distant metastasis in patients with familial early-stage breast cancer and high EZH2 expression. Breast Cancer Res Treat 2012, 132:429-437. 10.1007/s10549-011-1591-2, 3311223, 21614565.
16. Elston CW, Ellis IO. Pathological prognostic factors in breast cancer: I. the value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology 1991, 19:403-410. 10.1111/j.1365-2559.1991.tb00229.x, 1757079.
17. Rakha EA, El-Sayed ME, Menon S, Green AR, Lee AH, Ellis IO. Histologic grading is an independent prognostic factor in invasive lobular carcinoma of the breast. Breast Cancer Res Treat 2008, 111:121-127. 10.1007/s10549-007-9768-4, 17929165.
18. Sinha PS, Bendall S, Bates T. Does routine grading of invasive lobular cancer of the breast have the same prognostic significance as for ductal cancers?. Eur J Surg Oncol 2000, 26:733-737. 10.1053/ejso.2000.0994, 11087636.
19. Yoo KH, Hennighausen L. EZH2 methyltransferase and H3K27 methylation in breast cancer. Int J Biol Sci 2012, 8:59-65. 3226033, 22211105.
20. Jung SP, Lee SK, Kim S, Choi MY, Bae SY, Kim J, Kim M, Kil WH, Cho EY, Choe JH, Kim JH, Kim JS, Nam SJ, Lee JE. Invasive pleomorphic lobular carcinoma of the breast: clinicopathologic characteristics and prognosis compared with invasive ductal carcinoma. J Breast Cancer 2012, 15:313-319. 10.4048/jbc.2012.15.3.313, 3468785, 23091544.
21. Lopez-Garcia MA, Geyer FC, Lacroix-Triki M, Marchio C, Reis-Filho JS. Breast cancer precursors revisited: molecular features and progression pathways. Histopathology 2010, 57:171-192. 10.1111/j.1365-2559.2010.03568.x, 20500230.